CBU
AKRO

CIBC Bancorp USA’s Akero Therapeutics AKRO Stock Holding History

CIBC Bancorp USA’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$354K Buy
+7,451
New +$361K ﹤0.01% 1014

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIBC Bancorp USA's AKRO Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Akero Therapeutics (AKRO) in Q3 2025: 7,451 shares worth $354K. The stake represents ﹤0.01% of the portfolio and ranks #1014 among its holdings.

265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

  • CIBC Bancorp USA held 7,451 shares of Akero Therapeutics worth $354K as of Q3 2025.
  • Akero Therapeutics was a new CIBC Bancorp USA position in Q3 2025.
  • Akero Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1014 holding.
  • 265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.